文献速递免疫规划

缺乏磷脂酶A2活性的细小病毒B19病毒样颗粒疫苗的安全性与免疫原性

Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity.
PubMed 文献 · Vaccine · 2022-09-14

本研究设计了缺失磷脂酶A2(PLA2)结构域的细小病毒B19病毒样颗粒(⊿PLA2 B19 VLP),并在小鼠体内确认其免疫原性与安全性。⊿PLA2 B19 VLP免疫小鼠的免疫部位未出现组织学炎症反应,也未产生IL-6,而B19 VLP免疫小鼠则出现上述反应。⊿PLA2 B19 VLP诱导的中和抗体水平与B19血清阳性人样本相似,提示其可作为安全有效的B19疫苗候选。

要点

  • ⊿PLA2 B19 VLP免疫小鼠未出现免疫部位炎症反应及IL-6产生。
  • B19 PLA2结构域可能不构成主要CD4+ T细胞表位。
  • ⊿PLA2 B19 VLP诱导的中和抗体水平与B19血清阳性人样本相似。

核心结论

  • ⊿PLA2 B19 VLP可诱导针对B19的中和抗体,水平与B19血清阳性人样本相似,提示其可作为安全有效的B19疫苗候选。

研究设计与样本

  • 研究设计为体内实验,设计缺失PLA2结构域的B19 VLP(⊿PLA2 B19 VLP),并在小鼠中确认其免疫原性与安全性。

主要发现

  • ⊿PLA2 B19 VLP免疫小鼠的免疫部位未出现组织学炎症反应,也未产生IL-6,而B19 VLP免疫小鼠出现这些反应。
  • 来自VLP免疫小鼠和B19血清阳性人样本的CD4+ T细胞未被B19 PLA2刺激激活,提示B19 PLA2结构域不构成主要CD4+ T细胞表位。
  • ⊿PLA2 B19 VLP诱导的抗B19中和抗体水平与B19血清阳性人样本相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Parvovirus B19 (B19) belongs to the Erythroparvovirus genus and is known to cause the fifth disease in children. Primary infection of pregnant women is associated with a high risk of hydrops fetalis and stillbirth due to severe fetal anemia. Virus-like particle (VLP) vaccine candidates for B19 have been developed, although none have been approved so far. The B19 phospholipase A2 domain (B19 PLA2), located in the VP1 unique region, is believed to be associated with adverse inflammatory reactions, and previous effective attempts to improve this vaccine modality inserted a mutation to impair the PLA2 activity of VLPs. In this study, we designed VLPs with a deletion mutant of PLA2 (⊿PLA2 B19 VLP), devoid of PLA2 activity, and confirmed their immunogenicity and safe use in vivo. These results were supported by the lack of histological inflammatory reactions at the site of immunization or the production of IL-6 in ⊿PLA2 B19 VLP-immunized mice, that were observed in mice immunized with B19 VLPs. CD4+ T cells from mice vaccinated with VLPs and B19-seropositive human samples were not activated by B19 PLA2 stimulation, suggesting that the B19 PLA2 domain does not constitute a major CD4+ T cell epitope. Most importantly, the ⊿PLA2 B19 VLPs induced neutralizing antibodies against B19, in levels similar to those found in B19-seropositive human samples, indicating that they could be used as a safe and effective vaccine candidate against B19.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Suzuki H, Noguchi T, Matsugu N, et al. Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity. Vaccine. 2022. PMID: 36114131. doi:10.1016/j.vaccine.2022.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。